About the Company
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $HTBX News
Heat Biologics Takes Beating After Pricing $12 Million Stock Offering
Heat Biologics Inc. nosedived after the Durham, North Carolina-based biopharmaceutical company filed for a share offering pricing expected to hit $12 million. Heat Biologics Inc. nosedived after ...
Scorpius Holdings, Inc. Announces Closing of Public Offering
About Scorpius Holdings, Inc. Scorpius Holdings Inc. is an integrated large molecule ... For Investor Relations Inquiries: Heat Biologics NewsMORE Related Stocks ...
Heat Biologics Announces Planned Transfer to the NYSE American
Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announced today that it ...
Scorpius Holdings Inc (SCPX)
Heat Biologics, Inc.’s (NASDAQ:HTBX) shares plunged 56.1% during yesterday’s after-hours trading after the company presented disappointing top-line data from a phase ...
Harnessing the immune system to turn cold tumors hot
To address this unmet medical need, Heat Biologics is developing drug candidates that turn immunologically ‘cold’ tumors ‘hot’ with a fresh infiltrate of CD8 + killer T cells, enhancing ...
Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th
Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Jeff Wolf ...
A second co-founder has left Forge Biologics following its more than $600M acquisition
The co-founder and COO of Forge Biologics Inc. confirmed via message that he retired as of May 1, because he'd accomplished what he set out to build. Forge was acquired for more than $600 million in ...
A Radical New Experiment Used Synthetic Quartz To Capture Artificial Heat
Synthetic quartz may help reduce the carbon footprint of industries that produce things like glass, steel, and cement.
ADMA Biologics Inc ADMA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Innovent Biologics Inc 01801
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
IVBIY Innovent Biologics, Inc.
WXXWYWuXi Biologics (Cayman) Inc. Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology ...
Scorpius Holdings, Inc. Announces Pricing of Public Offering
Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the pricing of its underwritten ...
Loading the latest forecasts...